Table 1 Baseline characteristics (intention-to-treat population; n=481)
Characteristic | Aged 41–50 years (n=327) | Aged >50 years (n=154) |
|---|---|---|
Females, % | 72.7% | 66.9% |
Ethnicity: | ||
Caucasian | 74.6% | 73.4% |
Black | 2.1% | 0.0% |
Hispanic | 6.7% | 4.5% |
Asian | 8.9% | 16.2% |
other | 7.6% | 5.8% |
Age at study baseline, mean years (SD) | 45.1 (2.8) | 56.2 (4.2) |
Age at onset of clinical symptoms, mean years (SD) | 41.6 (5.9) | 50.7 (7.5) |
RRMS, %a | 96.3% | 94.9% |
SPMS, %b | 3.7% | 5.1% |
MS duration since onset of symptoms, mean years (SD) | 3.9 (5.2) | 5.9 (7.1) |
Relapses during last 2 years,a mean number (SD) | 1.7 (1.0) | 1.6 (1.1) |
≥2 relapses during last 2 years,a % | 55.6% | 52.7% |
EDSS, mean (SD) | 2.5 (1.5) | 3.1 (1.9) |
EDSS ≥3, % | 41.6% | 52.0% |
Cranial MRI performed, % | 96.3% | 94.0% |
Contrast-enhancing lesions, % | 28.8% | 22.7% |
DMT use prior to BEACON, % | 14.1% | 13.6% |